GCM
STLN

Graham Capital Management’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Graham Capital Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$104K Buy
+33,792
New +$104K ﹤0.01% 1036
2025
Q4 		– Sell
-72,408
Closed -$253K – 1582
2025
Q3 		$253K Sell
72,408
-13,798
-16% -$47.3K ﹤0.01% 936
2025
Q2 		$177K Buy
+86,206
New +$216K ﹤0.01% 1144

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Graham Capital Management's STLN Position: Q1 2026 in Review

Graham Capital Management opened a new position in Starling Oncology Institute, Inc. Common Stock (STLN) in Q1 2026: 33,792 shares worth $104K. The stake represents ﹤0.01% of the portfolio and ranks #1036 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in STLN as recently as Q3 2025.

Graham Capital Management first reported a position in STLN in Q2 2025 and has held it in 3 quarters since. The position peaked at $253K in Q3 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Graham Capital Management held 33,792 shares of Starling Oncology Institute, Inc. Common Stock worth $104K as of Q1 2026.
  • Starling Oncology Institute, Inc. Common Stock was a new Graham Capital Management position in Q1 2026.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Graham Capital Management's portfolio in Q1 2026, its #1036 holding.
  • Graham Capital Management first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2025 and has held it in 3 quarters since.
  • Graham Capital Management's Starling Oncology Institute, Inc. Common Stock position peaked at $253K in Q3 2025.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.